{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:05:55Z","timestamp":1777878355523,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bavarian Cancer Research Center"},{"DOI":"10.13039\/501100008384","name":"Stifterverband","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008384","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ixazomib is an oral proteasome inhibitor for relapsed\/refractory multiple myeloma (RRMM). Our study aimed to analyze the efficacy and tolerability of ixazomib-based combination therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a single-center retrospective analysis of 126 patients with RRMM and other plasma cell neoplasms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The median age was 65\u2009years, with a median of two prior therapy lines, and 16.7% were triple-class refractory. The overall response rate (ORR) was 52.5%; triple-class refractory patients had a significantly lower ORR than non-refractory controls (10.5% vs 60.2%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). After a median follow-up of 27.0\u2009months, the median progression-free survival (PFS) was 7.9\u2009months (95% CI: 6.9\u201311.0), and the median overall survival (OS) was 84.1\u2009months (95% CI: 68.1\u2013not reached). In multivariate analysis, a glomerular filtration rate of \u2a7d70\u2009ml\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      was linked to worse PFS (hazard ratio (HR): 2.11,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.008) and OS (HR: 7.27,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.003). Furthermore, triple-class refractory patients showed a trend toward inferior PFS (HR: 3.76,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.05) and significantly worse OS (HR: 20.46,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.002) compared to non-refractory patients. Grade \u2a7e3 hematologic adverse events occurred in 15.1% patients, while the most common non-hematologic adverse events were fatigue (5.6%) and peripheral neuropathy (26.2%), with the majority classified as grade 1\u20132.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Altogether, ixazomib regimens are potent in RRMM but are less effective in heavily pretreated patients and those with renal impairment, suggesting earlier use may yield greater benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207261421841","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T17:26:23Z","timestamp":1772299583000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5772-7700","authenticated-orcid":false,"given":"Xiang","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Mersi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Riedhammer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian J.","family":"Steinhardt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Bittrich","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 5, Klinikum N\u00fcrnberg Nord, N\u00fcrnberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"},{"name":"Mildred Scheel Early Career Center, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes M.","family":"Waldschmidt","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital W\u00fcrzburg, Oberd\u00fcrrbacher Street 6, W\u00fcrzburg 97080, Germany"},{"name":"Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9707-8"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71125-8"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00579-9"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12041035"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3209"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2949"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282225"},{"key":"e_1_3_4_12_2","first-page":"102","article-title":"Ninlaro (ixazomib): first oral proteasome inhibitor approved for the treatment of patients with relapsed or refractory multiple myeloma","volume":"9","author":"Raedler LA.","year":"2016","unstructured":"Raedler LA. Ninlaro (ixazomib): first oral proteasome inhibitor approved for the treatment of patients with relapsed or refractory multiple myeloma. Am Health Drug Benefits 2016; 9: 102\u2013105.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0581-8"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0038-8"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008787"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33003-4"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104353"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614"},{"issue":"12","key":"e_1_3_4_20_2","article-title":"Updates on blood transfusion guidelines","volume":"3","author":"The Lancet Haemotology","year":"2016","unstructured":"The Lancet Haemotology. Updates on blood transfusion guidelines. Lancet Haematol 2016; 3(12): e547.","journal-title":"Lancet Haematol"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04663-0"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03479-6"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05278-3"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26361"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00490-9"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11624-2"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00289-7"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014956"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01893"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261421841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261421841","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261421841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:18:16Z","timestamp":1777591096000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261421841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":29,"alternative-id":["10.1177\/20406207261421841"],"URL":"https:\/\/doi.org\/10.1177\/20406207261421841","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"20406207261421841"}}